Tuesday, November 24, 2009, 3:24pm SGT - The Singapore stock market closes in 1 hour and 36 minutes.
To create a watchlist or portfolio of shares, Register
FINANCE HOME PAGEINVESTINGFINANCE NEWS
    Market:       |  

Achillion Pharmaceuticals, Inc. (ACHN)

At 4:59AM SGT: 1.8699 USD  Down 0.0501 (2.61%)  
 MORE ON ACHN 
Quotes
HereSummary
Charts
News & Info
Company
Analyst Coverage
Ownership
Financials
 Achillion Pharmaceuticals, Inc. (NGM:ACHN) Delayed quote dataEdit
Last Trade:1.8699 USD
Trade Time:4:59AM SGT
Change:Down 0.0501 (2.61%)
Prev Close:1.92
Open:1.86
Bid:1.60 x 100
Ask:2.14 x 100
1y Target Est:4.50
Day's Range:1.85 - 1.88
52wk Range:0.65 - 2.42
Volume:5,844
Avg Vol (3m):32,780
Market Cap:49.84M
P/E (ttm):N/A
EPS (ttm):-1.053
Div & Yield:N/A (N/A%)
[Chart]
1d  5d  3m  6m  1y  2y  5y 
Use Y! Toolbar to track stocks
 Add ACHN to Portfolio   Download Data

 HEADLINES 
•ACHILLION PHARMACEUTICALS INC Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule
EDGAR Online (Wed, Nov 18)
•Achillion Receives Notice From NASDAQ
GlobeNewswire (Wed, Nov 18)
•New Star Analyst Rankings for Achillion Pharmaceuticals, Inc.
StarMine (Tue, Nov 10)
•Morningstar Strategist Says Healthcare Bill Will Be Law By End Of Year: Is Your Portfolio Ready?
Wall Street Transcript (Tue, Nov 10)
•ACHILLION PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements
EDGAR Online (Sat, Nov 7)
•Achillion Reports Third Quarter Results
GlobeNewswire (Fri, Nov 6)
•Achillion to Present at Three Upcoming Conferences
GlobeNewswire (Fri, Oct 30)
•Coverage initiated on Achillion Pharma by Wedbush Morgan
Briefing.com (Wed, Oct 21)
•Achillion Completes Phase 1a Trial of ACH-1625; Begins Dosing in Phase 1b Segment With HCV-Infected Patients
GlobeNewswire (Mon, Sep 28)
•ACHILLION PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement
EDGAR Online (Fri, Sep 4)
More Headlines for ACHN...
 ANALYST 
EPS Est (next year) (Dec-09) :-0.94
EPS Est (in 2 years) (Dec-10) :-0.62
Avg Rec (current)*:2.4
PEG Ratio:N/A
* (Strong Buy) 1.0 - 5.0 (Strong Sell)
Analyst Opinion - Estimates

 BUSINESS SUMMARY 
Achillion Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of treatments for infectious diseases.

Full Company Profile



Add to My Portfolio Add to Portfolio    Email to a Friend Email to a Friend
Get Summary for Another Symbol:
Search by Company
•Latest News•Singapore Indices